Search

Your search keyword '"Verheyen J"' showing total 281 results
Start Over Author "Verheyen J"
281 results on '"Verheyen J"'

1. Transmission of Human Immunodeficiency Virus I Drug Resistance - a Case Report. What are the Clinical Implications?

Author

Anadol E, Kaiser R, Verheyen J, Schülter E, Emmelkamp J, Schwarze-Zander C, Kupfer B, Wasmuth JC, and Rockstroh JK

Subjects
transmitted resistance, Drug Resistance, Human immunodeficiency virus I, T215 D, Medicine
Abstract

Abstract The success of first-line antiretroviral therapy can be challenged by the acquisition of primary drug resistance. Here we report a case where baseline genotypic resistance testing detected resistance conferring nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-associated mutations, but no primary mutations for protease inhibitor (PI). Subsequent PI-based HAART with boosted saquinavir led to virological treatment success with persistently undetectable viral load. After treatment simplification from saquinavir to an atazanavir based PI-therapy and no change in backbone therapy rapid virological breakthrough occurred. Retrospective analysis displayed preexisting gag cleavage site mutations which may have reduced the genetic barrier in a clinical relevant manner in combination with the already existing NRTI resistance mutations. Alternatively, this effect could be explained with a different antiviral potency for the respective PIs used.

Published
2010
Full Text
View/download PDF

2. Integrating climate model projections into environmental risk assessment: A probabilistic modeling approach

Author

Moe, SJ, Brix, KV, Landis, WG, Stauber, JL, Carriger, JF, Hader, JD, Kunimitsu, T, Mentzel, S, Nathan, R, Noyes, PD, Oldenkamp, R, Rohr, JR, van den Brink, PJ, Verheyen, J, Benestad, RE, Moe, SJ, Brix, KV, Landis, WG, Stauber, JL, Carriger, JF, Hader, JD, Kunimitsu, T, Mentzel, S, Nathan, R, Noyes, PD, Oldenkamp, R, Rohr, JR, van den Brink, PJ, Verheyen, J, and Benestad, RE

Published
2024

13. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, L. Hermans, L.E. Salpini, R. Di Carlo, D. Pas, S.D. Alvarez, M. Ben-Ari, Z. Boland, G. Bruzzone, B. Coppola, N. Seguin-Devaux, C. Dyda, T. Garcia, F. Kaiser, R. Köse, S. Krarup, H. Lazarevic, I. Lunar, M.M. Maylin, S. Micheli, V. Mor, O. Paraschiv, S. Paraskevis, D. Poljak, M. Puchhammer-Stöckl, E. Simon, F. Stanojevic, M. Stene-Johansen, K. Tihic, N. Trimoulet, P. Verheyen, J. Vince, A. Lepej, S.Z. Weis, N. Yalcinkaya, T. Boucher, C.A.B. Wensing, A.M.J. Perno, C.F. Svicher, V. HEPVIR working group of the European Society for translational antiviral research (ESAR)

Abstract

Background: HBsAg immune-escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains. Stop-codons can enhance HBV oncogenic-properties. Furthermore, as a consequence of the overlapping structure of HBV genome, some immune-escape mutations or stop-codons in HBsAg can derive from drug-resistance mutations in RT. This study is aimed at gaining insight in prevalence and characteristics of immune-associated escape mutations, and stop-codons in HBsAg in chronically HBV-infected patients experiencing nucleos(t)ide analogues (NA) in Europe. Methods: This study analyzed 828 chronically HBV-infected European patients exposed to ≥ 1 NA, with detectable HBV-DNA and with an available HBsAg-sequence. The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined. Mutations were defined as an aminoacid substitution with respect to a genotype A or D reference sequence. Results: At least one immune-associated escape mutation was detected in 22.1% of patients with rising temporal-trend. By multivariable-analysis, genotype-D correlated with higher selection of ≥ 1 immune-associated escape mutation (OR[95%CI]:2.20[1.32-3.67], P = 0.002). In genotype-D, the presence of ≥ 1 immune-associated escape mutations was significantly higher in drug-exposed patients with drug-resistant strains than with wild-type virus (29.5% vs 20.3% P = 0.012). Result confirmed by analysing drug-naïve patients (29.5% vs 21.2%, P = 0.032). Strong correlation was observed between sP120T and rtM204I/V (P < 0.001), and their co-presence determined an increased HBV-DNA. At least one NA-induced immune-escape mutation occurred in 28.6% of patients, and their selection correlated with genotype-A (OR[95%CI]:2.03[1.32-3.10],P = 0.001). Finally, stop-codons are present in 8.4% of patients also at HBsAg-positions 172 and 182, described to enhance viral oncogenic-properties. Conclusions: Immune-escape mutations and stop-codons develop in a large fraction of NA-exposed patients from Europe. This may represent a potential threat for horizontal and vertical HBV transmission also to vaccinated persons, and fuel drug-resistance emergence. © 2018 The Author(s).

Published
2018

14. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

Author

Piermatteo, L., primary, Battisti, A., additional, Carioti, L., additional, Anastasiou, O., additional, Gill, U.S., additional, Colagrossi, L., additional, Bertoli, A., additional, Aragri, M., additional, Iuvara, A., additional, Malagnino, V., additional, Cerva, C., additional, Lichtner, M., additional, Mastroianni, C.M., additional, De Sanctis, G.M., additional, Maurizio, P., additional, Marignani, M., additional, Pasquazzi, C., additional, Iapadre, N., additional, Mari, T., additional, Parruti, G., additional, Vecchiet, J., additional, Sarmati, L., additional, Andreoni, M., additional, Mario, A., additional, Grelli, S., additional, Kennedy, P., additional, Verheyen, J., additional, Silberstein, F. Ceccherini, additional, Perno, C.F., additional, Salpini, R., additional, and Svicher, V., additional

Published
2019
Full Text
View/download PDF

15. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, L. (Luna), Hermans, L.E. (Lucas Etienne), Salpini, R. (Romina), Di Carlo, D., Pas, S.D. (Suzan), Alvarez, M.R. (Marta), Ben Ari, Z. (Ziv), Boland, G.J. (Greet), Bruzzone, B. (Bianca), Coppola, N. (Nicola), Seguin-Devaux, C., Dyda, T. (Tomasz), Garcia, F. (Federico), Kaiser, R. (Rolf), Köse, S. (Sukran), Krarup, H.B. (H.), Lazarevic, I. (Ivana), Lunar, M.M. (Maja M.), Maylin, S. (Sarah), Micheli, V. (Valeria), Mor, O. (Orna), Paraschiv, C. (Corina), Paraskevis, D. (Dimitrios), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Simon, F. (François), Stanojevic, M. (Maja), Stene-Johansen, K. (Kathrine), Tihic, N. (Nijaz), Trimoulet, P. (Pascale), Verheyen, J. (Jens), Vince, A. (Adriana), Lepej, S.Z. (Snjezana), Weis, N. (Nina), Yalcinkaya, T. (Tülay), Boucher, C.A.B. (Charles), Wensing, A. (Amj), Perno, C.F. (Carlo), Svicher, V. (Valentina), Colagrossi, L. (Luna), Hermans, L.E. (Lucas Etienne), Salpini, R. (Romina), Di Carlo, D., Pas, S.D. (Suzan), Alvarez, M.R. (Marta), Ben Ari, Z. (Ziv), Boland, G.J. (Greet), Bruzzone, B. (Bianca), Coppola, N. (Nicola), Seguin-Devaux, C., Dyda, T. (Tomasz), Garcia, F. (Federico), Kaiser, R. (Rolf), Köse, S. (Sukran), Krarup, H.B. (H.), Lazarevic, I. (Ivana), Lunar, M.M. (Maja M.), Maylin, S. (Sarah), Micheli, V. (Valeria), Mor, O. (Orna), Paraschiv, C. (Corina), Paraskevis, D. (Dimitrios), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Simon, F. (François), Stanojevic, M. (Maja), Stene-Johansen, K. (Kathrine), Tihic, N. (Nijaz), Trimoulet, P. (Pascale), Verheyen, J. (Jens), Vince, A. (Adriana), Lepej, S.Z. (Snjezana), Weis, N. (Nina), Yalcinkaya, T. (Tülay), Boucher, C.A.B. (Charles), Wensing, A. (Amj), Perno, C.F. (Carlo), and Svicher, V. (Valentina)

Abstract

Background: HBsAg immune-escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains. Stop-codons can enhance HBV oncogenic-properties. Furthermore, as a consequence of the overlapping structure of HBV genome, some immune-escape mutations or stop-codons in HBsAg can derive from drug-resistance mutations in RT. This study is aimed at gaining insight in prevalence and characteristics of immune-associated escape mutations, and stop-codons in HBsAg in chronically HBV-infected patients experiencing nucleos(t)ide analogues (NA) in Europe. Methods: This study analyzed 828 chronically HBV-infected European patients exposed to ≥ 1 NA, with detectable HBV-DNA and with an available HBsAg-sequence. The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined. Mutations were defined as an aminoacid substitution with respect to a genotype A or D reference sequence. Results: At least one immune-associated escape mutation was detected in 22.1% of patients with rising temporal-trend. By multivariable-analysis, genotype-D correlated with higher selection of ≥ 1 immune-associated escape mutation (OR[95%CI]:2.20[1.32-3.67], P = 0.002). In genotype-D, the presence of ≥ 1 immune-associated escape mutations was significantly higher in drug-exposed patients with drug-resistant strains than with wild-type virus (29.5% vs 20.3% P = 0.012). Result confirmed by anal

Published
2018
Full Text
View/download PDF

16. Rapid rebound of a highly replication competent preexisting CXCR4-tropic HIV variant after allogeneic stem cell transplantation with CCR5D32 stem cells

Author

Verheyen, J., Thielen, A., Luebke, N., Dirks, M., Widera, M., Dittmer, U., Kordales, L., Daeumer, M., de Jong, D., Wensing, A., Kaiser, R., Nijhuis, M., Esser, S., Verheyen, J., Thielen, A., Luebke, N., Dirks, M., Widera, M., Dittmer, U., Kordales, L., Daeumer, M., de Jong, D., Wensing, A., Kaiser, R., Nijhuis, M., and Esser, S.

Published
2018

17. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, L, Hermans, Lucas, Salpini, R, Di Carlo, D, Pas, Suzan, Alvarez, M, Ben-Ari, Z, Boland, G, Bruzzone, B, Coppola, N, Seguin-Devaux, C, Dyda, T, Garcia, F, Kaiser, R, Kose, S, Krarup, H, Lazarevic, I, Lunar, MM, Maylin, S, Micheli, V, Mor, O, Paraschiv, S, Paraskevis, D, Poljak, M, Puchhammer-Stockl, E, Simon, F, Stanojevic, M, Stene-Johansen, K, Tihic, N, Trimoulet, P, Verheyen, J, Vince, A, Lepej, SZ, Weis, N, Yalcinkaya, T, Boucher, Charles, Wensing, AMJ, Perno, CF, Svicher, V, Colagrossi, L, Hermans, Lucas, Salpini, R, Di Carlo, D, Pas, Suzan, Alvarez, M, Ben-Ari, Z, Boland, G, Bruzzone, B, Coppola, N, Seguin-Devaux, C, Dyda, T, Garcia, F, Kaiser, R, Kose, S, Krarup, H, Lazarevic, I, Lunar, MM, Maylin, S, Micheli, V, Mor, O, Paraschiv, S, Paraskevis, D, Poljak, M, Puchhammer-Stockl, E, Simon, F, Stanojevic, M, Stene-Johansen, K, Tihic, N, Trimoulet, P, Verheyen, J, Vince, A, Lepej, SZ, Weis, N, Yalcinkaya, T, Boucher, Charles, Wensing, AMJ, Perno, CF, and Svicher, V

Published
2018

18. A hyper-glycosilation of HBV surface major hydrophilic correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro

Author

Colagrossi L, Salpini R, Surdo M, Battisti A, Pollicita M, Bertoli A, Di Santo F, Becker C, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V., Colagrossi, L, Salpini, R, Surdo, M, Battisti, A, Pollicita, M, Bertoli, A, Di Santo, F, Becker, C, Mastroianni, C, Marignani, M, Maylin, S, Delaugerre, C, Morisco, F, Coppola, N, Marrone, A, Sarmati, L, Andreoni, M, Angelico, M, Verheyen, J, Perno, Cf, and Svicher, V.

Published
2015

20. A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

Author

Salpini, R., primary, Piermatteo, L., additional, Battisti, A., additional, Colagrossi, L., additional, Aragri, M., additional, Fabeni, L., additional, Bertoli, A., additional, Mastroianni, C.M., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Nicola, C., additional, Marrone, A., additional, Iapadre, N., additional, Mario, A., additional, Sarmati, L., additional, Andreoni, M., additional, Verheyen, J., additional, Silberstein, F.C., additional, Levrero, M., additional, Perno, C.F., additional, Belloni, L., additional, and Svicher, V., additional

Published
2018
Full Text
View/download PDF

21. Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

Author

Salpini, R., primary, Battisti, A., additional, Carioti, L., additional, Carlo, D.D., additional, Anastasiou, O., additional, Gill, U.S., additional, Colagrossi, L., additional, Bertoli, A., additional, Aragri, M., additional, Fabeni, L., additional, Fini, V., additional, Piermatteo, L., additional, Iuvara, A., additional, Malagnino, V., additional, Cerva, C., additional, Lichtner, M., additional, Mastroianni, C.M., additional, Sanctis, G.M.D., additional, Maurizio, P., additional, Marignani, M., additional, Pasquazzi, C., additional, Iapadre, N., additional, Mari, T., additional, Parruti, G., additional, Vecchiet, J., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Grelli, S., additional, Kennedy, P., additional, Verheyen, J., additional, Silberstein, F.C., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2018
Full Text
View/download PDF

22. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

Author

Salpini, R, Surdo, M, Warner, N, Cortese, MF, Colledge, D, Soppe, S, Bellocchi, MC, Armenia, D, Carioti, L, Continenza, F, Di Carlo, D, Saccomandi, P, Mirabelli, C, Pollicita, M, Longo, R, Romano, S, Cappiello, G, Spano, A, Trimoulet, P, Fleury, H, Vecchiet, J, Iapadre, N, Barlattani, A, Bertoli, A, Mari, T, Pasquazzi, C, Missale, G, Sarrecchia, C, Orecchini, E, Michienzi, A, Andreoni, M, Francioso, S, Angelico, M, Verheyen, J, Ceccherini-Silberstein, F, Locarnini, S, Perno, CF, Svicher, V, Salpini, R, Surdo, M, Warner, N, Cortese, MF, Colledge, D, Soppe, S, Bellocchi, MC, Armenia, D, Carioti, L, Continenza, F, Di Carlo, D, Saccomandi, P, Mirabelli, C, Pollicita, M, Longo, R, Romano, S, Cappiello, G, Spano, A, Trimoulet, P, Fleury, H, Vecchiet, J, Iapadre, N, Barlattani, A, Bertoli, A, Mari, T, Pasquazzi, C, Missale, G, Sarrecchia, C, Orecchini, E, Michienzi, A, Andreoni, M, Francioso, S, Angelico, M, Verheyen, J, Ceccherini-Silberstein, F, Locarnini, S, Perno, CF, and Svicher, V

Abstract

BACKGROUND: An impaired HBsAg-secretion can increase HBV oncogenic-properties. Here, we investigate genetic-determinants in HBsAg correlated with HBV-induced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation. METHODS: This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry. RESULTS: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P <0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P <0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; P203Q+S210R:29±14%; wt:18%±9, P <0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P <0.001). CONCLUSIONS: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.

Published
2017

23. IMMUNE-ESCAPE MUTATIONS AND STOP-CODONS IN HBSAG CIRCULATES IN A RELEVANT PROPORTION OF PATIENTS WITH CHRONIC HBV INFECTION EXPOSED TO ANTI-HBV DRUGS IN EUROPE: IMPLICATIONS FOR HBV TRANSMISSION IN THE SETTING OF VACCINATION AND DISEASE PROGRESSION

Author

Colagrossi, L. Hermans, L. E. Salpini, R. Pas, S. D. and Alvarez, M. Ben Ari, Z. Boland, G. Bruzzone, B. Coppola, N. Seguin-Devaux, C. Dyda, T. Garcia, F. Kaiser, R. and Kose, S. Krarup, H. Lazarevic, I. Lunar, M. M. Maylin, S. Micheli, V. Mor, O. Paraschiv, S. Paraskevis, D. and Poljak, M. Puchhammer-Stoeckl, E. Simon, F. Stanojevic, M. and Stene-Johansen, K. Tihic, N. Trimoulet, P. Verheyen, J. and Vince, A. Weis, N. Yalcinkaya, T. Lepej, S. Z. and Boucher, C. A. Wensing, A. M. Perno, C. F. Svicher, V. and European Soc Translational

Published
2016

24. Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE)

Author

Hermans, L.E. Svicher, V. Pas, S.D. Salpini, R. Alvarez, M. Ben Ari, Z. Boland, G. Bruzzone, B. Coppola, N. Seguin-Devaux, C. Dyda, T. Garcia, F. Kaiser, R. Köse, S. Krarup, H. Lazarevic, I. Lunar, M.M. Maylin, S. Micheli, V. Mor, O. Paraschiv, S. Paraskevis, D. Poljak, M. Puchhammer-Stöckl, E. Simon, F. Stanojevic, M. Stene-Johansen, K. Tihic, N. Trimoulet, P. Verheyen, J. Vince, A. Weis, N. Yalcinkaya, T. Lepej, S.Z. Perno, C. Boucher, C.A.B. Wensing, A.M.J.

Abstract

Background European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. Methods A survey was performed on genotypic resistance testing results acquired during routine monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers. Results Data from 1568 patients were included. The majority (73.8%) were exposed to lamivudine monotherapy. Drug-resistant strains were detected in 52.7%. The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%). In patients exposed to entecavir (n = 102), full resistance was present in 35.3%. Independent risk factors for resistance were age, viral load, and lamivudine exposure (P

Published
2016

26. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

Author

Salpini, R., primary, Battisti, A., additional, Anastasiou, O., additional, Gill, U., additional, Colagrossi, L., additional, Bertoli, A., additional, Fabeni, L., additional, Fini, V., additional, Piermatteo, L., additional, Iuvara, A., additional, Malagnino, V., additional, Cerva, C., additional, Lichtner, M., additional, Mastroianni, C., additional, De Sanctis, G., additional, Paoloni, M., additional, Marignani, M., additional, Pasquazzi, C., additional, Iapadre, N., additional, Mari, T., additional, Parruti, G., additional, Vecchiet, I., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Grelli, S., additional, Kennedy, P., additional, Verheyen, J., additional, Perno, C.-F., additional, and Svicher, V., additional

Published
2017
Full Text
View/download PDF

27. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

Author

Salpini, R., primary, Battisti, A., additional, Anastasiou, O., additional, Gill, U., additional, Colagrossi, L., additional, Bertoli, A., additional, Fabeni, L., additional, Fini, V., additional, Piermatteo, L., additional, Iuvara, A., additional, Malagnino, V., additional, Cerva, C., additional, Lichtner, M., additional, Mastroianni, C., additional, De Sanctis, G., additional, Paoloni, M., additional, Marignani, M., additional, Pasquazzi, C., additional, Iapadre, N., additional, Mari, T., additional, Parruti, G., additional, Vecchiet, J., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Grelli, S., additional, Kennedy, P., additional, Verheyen, J., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2017
Full Text
View/download PDF

31. IMMUNE-ESCAPE MUTATIONS AND STOP-CODONS IN HBSAG CIRCULATES IN A RELEVANT PROPORTION OF PATIENTS WITH CHRONIC HBV INFECTION EXPOSED TO ANTI-HBV DRUGS IN EUROPE: IMPLICATIONS FOR HBV TRANSMISSION IN THE SETTING OF VACCINATION AND DISEASE PROGRESSION

Author

Colagrossi, L., Hermans, L. E., Salpini, R., Pas, S. D., Alvarez, M., Ben Ari, Z., Boland, G., Bruzzone, B., Coppola, N., Seguin-Devaux, C., Dyda, T., Garcia, F., Kaiser, R., Kose, S., Krarup, H., Lazarevic, I., Lunar, M. M., Maylin, S., Micheli, V., Mor, O., Paraschiv, S., Paraskevis, D., Poljak, M., Puchhammer-Stoeckl, E., Simon, F., Stanojevic, M., Stene-Johansen, K., Tihic, N., Trimoulet, P., Verheyen, J., Vince, A., Weis, N., Yalcinkaya, T., Lepej, S. Z., Boucher, C. A., Wensing, A. M., Perno, C. F., Svicher, V., Colagrossi, L., Hermans, L. E., Salpini, R., Pas, S. D., Alvarez, M., Ben Ari, Z., Boland, G., Bruzzone, B., Coppola, N., Seguin-Devaux, C., Dyda, T., Garcia, F., Kaiser, R., Kose, S., Krarup, H., Lazarevic, I., Lunar, M. M., Maylin, S., Micheli, V., Mor, O., Paraschiv, S., Paraskevis, D., Poljak, M., Puchhammer-Stoeckl, E., Simon, F., Stanojevic, M., Stene-Johansen, K., Tihic, N., Trimoulet, P., Verheyen, J., Vince, A., Weis, N., Yalcinkaya, T., Lepej, S. Z., Boucher, C. A., Wensing, A. M., Perno, C. F., and Svicher, V.

Published
2016

34. Immune-Escape Mutations and Stop-Codons in HBsAg Circulates in a Relevant Proportion of Patients with Chronic HBV Infection Exposed to Anti-HBV Drugs in Europe: Implications for HBV Transmission in the Setting of Vaccination and Disease Progression

Author

Colagrossi, L., primary, Hermans, L.E., additional, Salpini, R., additional, Pas, S.D., additional, Alvarez, M., additional, Ben Ari, Z., additional, Boland, G., additional, Bruzzone, B., additional, Coppola, N., additional, Seguin-Devaux, C., additional, Dyda, T., additional, Garcia, F., additional, Kaiser, R., additional, Köse, S., additional, Krarup, H., additional, Lazarevic, I., additional, Lunar, M.M., additional, Maylin, S., additional, Micheli, V., additional, Mor, O., additional, Paraschiv, S., additional, Paraskevis, D., additional, Poljak, M., additional, Puchhammer-Stöckl, E., additional, Simon, F., additional, Stanojevic, M., additional, Stene-Johansen, K., additional, Tihic, N., additional, Trimoulet, P., additional, Verheyen, J., additional, Vince, A., additional, Weis, N., additional, Yalcinkaya, T., additional, Lepej, S.Z., additional, Boucher, C.A., additional, Wensing, A.M., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2016
Full Text
View/download PDF

35. A HYPER-GLYCOSYLATION OF HBV SURFACE MAJOR HYDROPHILIC REGION CORRELATES WITH IMMUNOSUPPRESSION-DRIVEN HBV REACTIVATION AND HAMPERS HBSAG RECOGNITION IN VITRO

Author

Colagrossi, L., Salpini, R., Surdo, M., Battisti, A., Pollicita, M., Bertoli, A., Di Santo, F., Becker, C., Mastroianni, C., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Sarmati, L., Andreoni, M., Angelico, M., Verheyen, J., Perno, C. F., Svicher, V., Colagrossi, L., Salpini, R., Surdo, M., Battisti, A., Pollicita, M., Bertoli, A., Di Santo, F., Becker, C., Mastroianni, C., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Sarmati, L., Andreoni, M., Angelico, M., Verheyen, J., Perno, C. F., and Svicher, V.

Published
2015

36. SAT-350 - A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

Author

Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Fabeni, L., Bertoli, A., Mastroianni, C.M., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Nicola, C., Marrone, A., Iapadre, N., Mario, A., Sarmati, L., Andreoni, M., Verheyen, J., Silberstein, F.C., Levrero, M., Perno, C.F., Belloni, L., and Svicher, V.

Published
2018
Full Text
View/download PDF

37. FRI-293 - Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

Author

Salpini, R., Battisti, A., Carioti, L., Carlo, D.D., Anastasiou, O., Gill, U.S., Colagrossi, L., Bertoli, A., Aragri, M., Fabeni, L., Fini, V., Piermatteo, L., Iuvara, A., Malagnino, V., Cerva, C., Lichtner, M., Mastroianni, C.M., Sanctis, G.M.D., Maurizio, P., Marignani, M., Pasquazzi, C., Iapadre, N., Mari, T., Parruti, G., Vecchiet, J., Sarmati, L., Andreoni, M., Angelico, M., Grelli, S., Kennedy, P., Verheyen, J., Silberstein, F.C., Perno, C.F., and Svicher, V.

Published
2018
Full Text
View/download PDF

40. Unterschiede in der Frameshift-regulierenden p1-Region in therapie-naiven und PI-resistenten HIV

Author

Knops, E., Théberge-Julien, G., Kaiser, R., Hoffmann, D., Brakier-Gingras, L., and Verheyen, J.

Subjects
ddc: 610, viruses, 610 Medical sciences, Medicine
Abstract

Objectives: The HIV replication cycle include a maturation step, in which the viral enzymes are cleaved from the Gag-Pol precursor built due to a frameshift event in p1. Two Gag cleavage-sites (CS) (p7/p1, p1/p6-gag), which were found to be important in PI-resistant HIV, and Pol CS (p7/TFP,[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Published
2010

41. Coinfektion mit Hepatitis B und C bei therapienaiven HIV-Patienten - Prävalenz und Risikofaktoren

Author

Reuter, S., Oette, M., Wilhelm, F. C., Kaiser, R., Balduin, M., Schweizer, F., Verheyen, J., Adams, O., Beggel, B., Häussinger, D., and RESINA Studiengruppe

Subjects
ddc: 610, virus diseases, 610 Medical sciences, Medicine, digestive system diseases
Abstract

Introduction: In HIV treatment-naïve patients we analyzed the prevalence of serological and molecular markers for hepatitis B virus (HBV) and hepatitis C virus (HCV). We aimed at the identification of risk factors for chronic or occult hepatitis B infection (oHBV) and HCV infection. Patients,[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Published
2010

42. Häufigkeit von HBsAg (Hepatitis B surface-antigen) Mutationen in Isolaten resistenter Hepatitis B-Viren

Author

Neumann-Fraune, M., Sichtig, N., Obermeier, M., Berg, T., Beggel, B., Glebe, D., Kaiser, R., and Verheyen, J.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: Chronic HBV infection can cause liver-cirrhosis or hepatocellular carcinoma. Different antiviral therapy regimens are used to influence the disease progression. An obstacle regarding sustained suppression of viral replication are emerging drug-resistances. Due to overlapping reading-frames[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Published
2010

43. P0625 : A hyper-glycosylation of HBV surface major hydrophilic region characterizes HBV reactivation driven by immunosuppression and affects HBsAg recognition in vitro

Author

Salpini, R., primary, Surdo, M., additional, Colagrossi, L., additional, Battisti, A., additional, Pollicita, M., additional, Bertoli, A., additional, Di Santo, F., additional, Becker, C., additional, Mastroianni, C., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Coppola, N., additional, Marrone, A., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Verheyen, J., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2015
Full Text
View/download PDF

44. A hyper-glycosylation of HBV surface major hydrophilic region correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro

Author

Colagrossi, L., primary, Salpini, R., additional, Surdo, M., additional, Battisti, A., additional, Pollicita, M., additional, Bertoli, A., additional, Di Santo, F., additional, Becker, C., additional, Mastroianni, C., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Coppola, N., additional, Marrone, A., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Verheyen, J., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2015
Full Text
View/download PDF

46. Time on drug analysis based on real life data

Author

Schuelter, E., Kaiser, R., Zazzi, M., Soennerborg, A., Camacho, R., Verheyen, J., Schuelter, E., Kaiser, R., Zazzi, M., Soennerborg, A., Camacho, R., and Verheyen, J.

Published
2014

48. Tunable switching dynamics of a single Si dopant in GaAs(110)

Author

Smakman, E.P., Helgers, P.L.J., Verheyen, J., Koenraad, P.M., Möller, R., Smakman, E.P., Helgers, P.L.J., Verheyen, J., Koenraad, P.M., and Möller, R.

Abstract

The dynamic behavior of single bistable Si dopants in the GaAs (110) surface, which switch between a positive and a negative charge configuration, was investigated using a scanning tunneling icroscope (STM) and noise analysis electronics. The dopant atom switching frequency shows a clear dependence on the bias voltage and tunneling current, because these parameters influence the escape and capture processes of electrons. Our physical model for these processes, taking into account the relevant tunneling barriers, matches well with the experimental data. By choosing the appropriate tunneling conditions, we show that a single dopant can be employed as a memory element. The STM tip serves both as an electrical gate to write and as a probe to read the information stored on a single Si atom.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results